“Inhibiting DGKi seems to reverse the effects of cystic fibrosis”
Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg and Regensburg University, both in Germany, and the University of Lisboa, in Portugal, have discovered a promising potential drug target for cystic fibrosis. Their work, published online today in Cell, also uncovers a large set of genes not previously linked to the disease, demonstrating how a new screening technique can help identify new drug targets.
Cystic fibrosis is a hereditary disease caused by mutations in a single gene called CFTR. These mutations cause problems in various organs, most notably making the lining of the lungs secrete unusually thick mucus. This leads to recurrent life-threatening lung infections, which make it increasingly hard for patients to breathe. The disease is estimated to affect 1 in every 2500-6000 newborns in Europe.
In patients with cystic fibrosis, the mutations to CFTR render it unable to carry out its normal tasks. Among other things, this means CFTR loses the ability to control a protein called the epithelial sodium channel (ENaC). Released from CFTR’s control, ENaC becomes hyperactive, cells in the lungs absorb too much sodium and – as water follows the sodium – the mucus in patients’ airways becomes thicker and the lining of the lungs becomes dehydrated. The only drug currently available that directly counteracts a cystic fibrosis-related mutation only works on the three percent of patients that carry one specific mutation out of the almost 2000 CFTR mutations scientists have found so far.
Thus, if you were looking for a more efficient way to fight cystic fibrosis, finding a therapy that would act upon ENaC instead of trying to correct that multitude of CFTR mutations would seem like a good option. But unfortunately, the drugs that inhibit ENaC, mostly developed to treat hypertension, don’t transfer well to cystic fibrosis, where their effects don’t last very long. So scientists at EMBL, Regensburg University and University of Lisboa set out to find alternatives.
“In our screen, we attempted to mimic a drug treatment,” says Rainer Pepperkok, whose team at EMBL developed the technique, “we’d knock down a gene and see if ENaC became inhibited.”
Starting with a list of around 7000 genes, the scientists systematically silenced each one, using a combination of genetics and automated microscopy, and analysed how this affected ENaC. They found over 700 genes which, when inhibited, brought down ENaC activity, including a number of genes no-one knew were involved in the process. Among their findings was a gene called DGKi. When they tested chemicals that inhibit DGKi in lung cells from cystic fibrosis patients, the scientists discovered that it appears to be a very promising drug target.
“Inhibiting DGKi seems to reverse the effects of cystic fibrosis, but not block ENaC completely,” says Margarida Amaral from the University of Lisboa, “indeed, inhibiting DGKi reduces ENaC activity enough for cells to go back to normal, but not so much that they cause other problems, like pulmonary oedema.”
The Latest on: Cystic fibrosis
Saratoga County singer won’t let cystic fibrosis stand in the way of her dreams
on June 20, 2018 at 3:12 pm
What's your passion? What's that one hobby or pastime that fuels your soul? Now imagine having a medical condition that could take it from you. A young woman from Saratoga County doesn't have to imagine. She lives it every day, but her spirit and ... […]
Agasi 7 rooftop party raising money for Cystic Fibrosis Foundation
on June 20, 2018 at 2:57 pm
Rachel Sims who is an honoree for the Cystic Fibrosis Foundation's Tase of the Finest was on Good Afternoon Arkansas talking about a special event she is holding raising money and awareness for Cystic Fibrosis and on Wednesday, June 20th at Agasi 7 Rooftop ... […]
Constable: Northwestern next for Plainfield author with cystic fibrosis
on June 20, 2018 at 2:19 pm
A top scholar and published author who recently won a scholarship she'll use in the fall at Northwestern University, Ravina Thakkar spends four hours a day doing something more important than academics. Every morning and every night, the Plainfield 18-year ... […]
Vertex doubles size of cystic fibrosis drug discovery site
on June 19, 2018 at 6:31 am
Vertex has more than doubled the size of the San Diego research site that discovered its key cystic fibrosis drugs. The newly expanded site covers 170,000 square feet, boosting Vertex’s ability to hunt for the next generation of blockbusters. Boston ... […]
Vertex Pharmaceuticals opens expanded San Diego research center with focus on cystic fibrosis
on June 18, 2018 at 5:24 pm
Jennifer Ferguson, a San Diego mother of two children with cystic fibrosis, praises Vertex Pharmaceuticals for developing drugs for the genetic disease. (Bradley J. Fikes) Vertex Pharmaceuticals opened its new San Diego research center Monday, starting a ... […]
Health Matters: Screening for Cystic Fibrosis
on June 18, 2018 at 6:05 am
It can affect a baby’s lungs, digestive system and pancreas, doctors say cystic fibrosis is an autosomal recessive disorder that many parents have no idea they carry. “We recommend by the American College of OBGYN guidelines, that all pregnant patients ... […]
Cystic Fibrosis Market Robust Expansion by Top Key Manufactures, Demand and Supply to 2023
on June 14, 2018 at 11:17 am
Cystic fibrosis (CF) is a chronic, genetic disease which affects the overall progress of entire body leading to severe disability and early death in many cases. CF is mainly caused due to several mutations in the gene which encodes for cystic fibrosis ... […]
Exclusive Cover Reveal: Teens with Cystic Fibrosis Fall in Love in Rachael Lippincott's Five Feet Apart
on June 14, 2018 at 9:44 am
Falling in love while living in a hospital is…complicated. And when you’re both cystic fibrosis patients who must stay five feet apart at all times, it’s nearly impossible. Here’s a first look at the stars of Five Feet Apart. This November, Simon ... […]
Vertex Gets Some Breathing Room As Rival Disappoints In Cystic Fibrosis
on June 7, 2018 at 9:46 am
Vertex Pharmaceuticals (VRTX) is getting some breathing room, an analyst said Thursday, as rival Proteostasis (PTI) tumbled on disappointing results from a study testing cystic fibrosis drugs. Proteostasis tested its drug, PTI-801, in patients also taking ... […]
via Google News and Bing News